These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22890325)

  • 1. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.
    Deeraksa A; Pan J; Sha Y; Liu XD; Eissa NT; Lin SH; Yu-Lee LY
    Oncogene; 2013 Jun; 32(24):2973-83. PubMed ID: 22890325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
    Zhang Z; Chen L; Wang H; Ahmad N; Liu X
    Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
    Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
    J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
    Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
    J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
    Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
    Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
    Jemaà M; Kifagi C; Serrano SS; Massoumi R
    Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
    Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
    Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.
    Chen L; Ahmad N; Liu X
    Cell Cycle; 2016; 15(6):840-9. PubMed ID: 26900800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.
    Zhang Z; Zhang G; Kong C
    J Cell Mol Med; 2017 Apr; 21(4):758-767. PubMed ID: 27878946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
    Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
    Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
    Shin SB; Woo SU; Chin YW; Jang YJ; Yim H
    J Cell Physiol; 2017 Oct; 232(10):2818-2828. PubMed ID: 27861885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.